Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139468 | 1.00 | CYP11B2 (0.35) | CYP11B2CYP11B1SCN9ALRRK2HRH2 | |
| SCHEMBL2142042 | 0.88 | XDH (0.43) | CYP11B2CYP11B1SCN9ASLC22A12XDH | |
| SCHEMBL2142044 | 0.88 | XDH (0.43) | CYP11B2CYP11B1SCN9ASLC22A12XDH | |
| SCHEMBL2139165 | 0.86 | CYP11B1 (0.40) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL2140425 | 0.86 | CTSA (0.38) | — | |
| SCHEMBL2143426 | 0.86 | CYP11B1 (0.40) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL2137841 | 0.86 | CTSA (0.38) | — | |
| SCHEMBL2140938 | 0.86 | CYP11B2 (0.36) | CYP11B2CYP11B1SCN9AEGLN1XDH | |
| SCHEMBL2140945 | 0.86 | CYP11B2 (0.36) | CYP11B2CYP11B1SCN9AEGLN1XDH | |
| SCHEMBL3395304 | 0.84 | ABL1 (0.35) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148407-B2 | Compounds derived from 5-thioxylose and their use in therapeutics | LABORATORIES FOURNIER S.A. (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1861411-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100413-A9 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | FOURNIER LAB SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100413-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | CYP11B2 222/4885CYP11B1 221/4885SCN9A 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.